MS Drug's immune impact revealed in small study
NCT ID NCT06415864
First seen Feb 04, 2026 · Last updated May 23, 2026 · Updated 15 times
Summary
This study looked at how the oral medication cladribine changes different types of immune cells in people with relapsing-remitting multiple sclerosis (RRMS). Ten participants were followed for 96 weeks, with blood and spinal fluid samples taken to measure B cells, T cells, and other immune markers. The goal was to understand the drug's effects on the immune system, not to test if it works as a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Barts Health NHS Trust
London, United Kingdom
Conditions
Explore the condition pages connected to this study.